What does this company do and how does it make money?

Amgen operates a diversified pharmaceutical portfolio where no single drug creates concentration risk. The strong correlation with inflation suggests pricing power, while the inverse relationship with consumer sentiment reflects healthcare's defensive nature — people need medicine regardless of economic conditions.

Five legendary investment frameworks analyzed this company.

Buffett sees a pharmaceutical fortress with 39.8% margins trading at a 68.6% discount to value, while Graham warns that 33x earnings can't be justified by any margin — even one that doubled in two years. Explore each framework's full analysis to understand their reasoning.

How much cash does it generate and where does it go?

Amgen generates substantial cash but reinvests aggressively — R&D spending now exceeds operating cash flow as the company funds late-stage pipeline development including MariTide obesity drug. The combination of debt reduction and minimal buybacks signals confidence in organic growth over financial engineering.

Is the business getting stronger or weaker?

The business is demonstrating exceptional operating leverage — every 1% of revenue growth drives 15.8% operating income growth. The margin expansion from mid-teens to nearly 40% in two years, combined with ROIC approaching decade highs, indicates fundamental business improvement beyond typical cyclical fluctuations.

What could go wrong and has it survived trouble before?

The market has positioned itself for perfection — any disappointment triggers severe punishment while positive surprises generate minimal reward. However, management's net insider buying during the margin expansion suggests confidence in sustainability, and the company has demonstrated resilience by recovering from past shocks within 1-2 quarters.

Operating margins doubled from 15.5% to 39.8% in two years while the market implies only 1.43% perpetual growth.

Is the stock priced for perfection, fair value, or pessimism?

The market appears deeply skeptical — pricing in minimal growth despite 10% FCF expansion and record margins. The 68.6% discount to DCF valuation suggests either the market sees risks not captured in current financials or represents a significant expectations gap for a business hitting operational peaks.